Indiana University Researchers Identify Weight-Loss Mechanism That Eliminates Need for GLP-1 Hormones

New research shows glucagon and GIP activity can achieve weight loss without GLP-1, eliminating common gastrointestinal side effects for obesity patients.

By: AXL Media

Published: May 1, 2026, 7:48 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Patient Centric Pivot in Obesity Treatment

A new study published in April 2026 suggests that the dominant "secret sauce" of current weight management drugs, the GLP-1 hormone, may not be essential for achieving significant weight loss. Led by Richard DiMarchi of Indiana University Bloomington and Matthias Tschöp of the Ludwig Maximilian University of Munich, the research identifies a potent metabolic alternative. By focusing on a combination of glucagon and gastrointestinal peptide agonism, the team has found a way to maintain efficacy while potentially eliminating the severe gastrointestinal side effects that frequently lead patients to discontinue existing therapies like Wegovy and Zepbound.

Unmasking the Potency of Alternative Hormones

The breakthrough occurred when researchers began to "supercharge" metabolic peptides by adding various hormone activities to leading edge treatments. In the process, they discovered that the appetite suppressing effects of GLP-1 were actually camouflaging the potent weight loss capabilities of other hormones. According to DiMarchi, once the GLP-1 was removed from triple agonist peptides, the combination of glucagon and GIP alone proved sufficient to restore normal weight in obese rodents and monkeys. This suggests that the biological reliance on GLP-1 for weight management may be less absolute than previously assumed.

Addressing the Barriers to Long Term Compliance

While GLP-1 drugs are recognized as effective, their utility is often limited by a patient's ability to tolerate the nausea and other gastrointestinal distress they cause. The current clinical landscape requires lengthy dosage adjustments to mitigate these effects, a hurdle that prevents many individuals from ever initiating treatment. This new research, funded by the startup Bluewater Biosciences, aims to create a "patient centric" therapy that achieves comparable results without the physical toll on the digestive system, making peptide medicines accessible to a much broader pool of patients.